The effects of hormone replacement therapy on plasma lipids in type II diabetes

被引:20
作者
Manwaring, P
Morfis, L
Diamond, T
Howes, LG
机构
[1] Univ New S Wales, St George Hosp, Dept Clin Pharmacol, Kogarah, NSW 2217, Australia
[2] Univ New S Wales, Dept Aged Care, Kogarah, NSW 2217, Australia
[3] Univ New S Wales, St George Hosp, Dept Endocrinol, Kogarah, NSW 2217, Australia
关键词
hormone; equine estrogen; cholesterol levels;
D O I
10.1016/S0378-5122(99)00112-7
中图分类号
R592 [老年病学]; C [社会科学总论];
学科分类号
03 ; 0303 ; 100203 ;
摘要
Objectives: The effects of hormone replacement therapy on cardiovascular risk factors in postmenopausal women with non-insulin dependent diabetes mellitus (type II diabetes) is uncertain. Methods: The effects of estrogen replacement therapy (ERT, conjugated equine estrogen 0.625 mg orally daily), combined estrogen and continuous progestogen therapy (HRT, 0.625 mg of conjugated equine estrogens plus medroxyprogesterone acetate 5 mg daily) or placebo was compared in 20 postmenopausal type II diabetic women and 20 normal postmenopausal women in a double blind, randomised, crossover study. Patients receiving insulin were excluded from the study and all lipid modifying drugs were ceased at least 4 weeks prior to randomisation. Other medication including oral hypoglycaemics was kept constant for the duration of the study. Results: Women with type IT diabetes were a similar age (58.7 +/- 1.3 years) to the non-diabetic women (59.6 +/- 1.6 years) but they had a significantly greater body mass index, a higher incidence of treated hypertension, higher fasting plasma glucose levels, higher triglycerides and lower HDL cholesterol levels than non-diabetic women. ERT reduced total cholesterol and LDL cholesterol by a similar extent (8.9-12.3%) in normal and type II diabetic women and increased HDL cholesterol to a similar extent in both groups (11.0 and 8.9% respectively). ERT did not significantly alter fasting triglyceride levels in either group. The addition of medroxyprogesterone acetate 5 mg daily abolished the increase in HDL cholesterol associated with ERT in both groups but did not significantly affect any of the other lipid measurements. ERT and HRT did not significantly alter fasting insulin levels nor alter fasting glucose levels in either non-diabetic women or women with type II diabetes. Conclusions: ERT and HRT have similar effects on lipids in women with type II diabetes and non-diabetic women after 1 month of therapy. (C) 2000 Elsevier Science Ireland Ltd. All rights reserved.
引用
收藏
页码:239 / 247
页数:9
相关论文
共 31 条
  • [1] Estrogen replacement therapy decreases hyperandrogenicity and improves glucose homeostasis and plasma lipids in postmenopausal women with noninsulin-dependent diabetes mellitus
    Andersson, B
    Mattsson, LA
    Hahn, L
    Marin, P
    Lapidus, L
    Holm, G
    Bengtsson, BA
    Bjorntorp, P
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1997, 82 (02) : 638 - 643
  • [2] ASSMANN G, 1989, AM J CARDIOL, V63, pH33
  • [3] POSTMENOPAUSAL ESTROGEN USE AND HEART-DISEASE RISK-FACTORS IN THE 1980S - RANCHO-BERNARDO, CALIF, REVISITED
    BARRETTCONNOR, E
    WINGARD, DL
    CRIQUI, MH
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1989, 261 (14): : 2095 - 2100
  • [4] BERGER GMB, 1995, DIABETIC MED, V12, P788, DOI 10.1111/j.1464-5491.1995.tb02081.x
  • [5] Bjorntorp Per, 1994, Current Opinion in Lipidology, V5, P166, DOI 10.1097/00041433-199405030-00003
  • [6] Effect of 17 beta-estradiol on plasma lipids and LDL oxidation in postmenopausal women with type II diabetes mellitus
    Brussaard, HE
    Leuven, JAG
    Kluft, C
    Krans, HMJ
    vanDuyvenvoorde, W
    Buytenhek, R
    vanderLaarse, A
    Princen, HMG
    [J]. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 1997, 17 (02) : 324 - 330
  • [7] RELATIONSHIP OF PLASMA-INSULIN LEVELS TO THE INCIDENCE OF MYOCARDIAL-INFARCTION AND CORONARY HEART-DISEASE MORTALITY IN A MIDDLE-AGED POPULATION
    DUCIMETIERE, P
    ESCHWEGE, E
    PAPOZ, L
    RICHARD, JL
    CLAUDE, JR
    ROSSELIN, G
    [J]. DIABETOLOGIA, 1980, 19 (03) : 205 - 210
  • [8] Reduced mortality associated with long-term postmenopausal estrogen therapy
    Ettinger, B
    Friedman, GD
    Bush, T
    Quesenberry, CP
    [J]. OBSTETRICS AND GYNECOLOGY, 1996, 87 (01) : 6 - 12
  • [9] FROHLICH JJ, 1991, PRIMARY HYPERLIPOPRO, P143
  • [10] INSULIN-RESISTANCE, SECRETION, AND ELIMINATION IN POSTMENOPAUSAL WOMEN RECEIVING ORAL OR TRANSDERMAL HORMONE REPLACEMENT THERAPY
    GODSLAND, IF
    GANGAR, K
    WALTON, C
    CUST, MP
    WHITEHEAD, MI
    WYNN, V
    STEVENSON, JC
    [J]. METABOLISM-CLINICAL AND EXPERIMENTAL, 1993, 42 (07): : 846 - 853